SCHEMBL24809015

SCHEMBL24809015

CC(C)Cc1cccc(-c2cccnc2CC(C)C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 3/20 0.40
PDE4B Q07343 3/20 0.40
PDE4C Q08493 3/20 0.40
PDE4D Q08499 3/20 0.40
CTSS P25774 1/20 0.40
CTSK P43235 1/20 0.40
MAP4K4 O95819 1/20 0.37
GCK P35557 1/20 0.36
DRD2 P14416 2/20 0.35
DRD4 P21917 2/20 0.35
DRD3 P35462 2/20 0.35
HTR7 P34969 1/20 0.35
NMT1 P30419 3/20 0.35
CYP2C9 P11712 2/20 0.34
EPHX2 P34913 1/20 0.34
PRMT6 Q96LA8 1/20 0.34
MAPK1 P28482 1/20 0.34
PLA2G10 O15496 3/20 0.33
PLA2G2A P14555 3/20 0.33
PTGER1 P34995 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10130795 0.79 CLK4 (0.47) PDE4APDE4BPDE4CPDE4DCTSS
SCHEMBL28161128 0.76 CTSS (0.48) CTSSCTSK
SCHEMBL12435670 0.75 HRH3 (0.52) CTSSCTSKHTR7MAPK1
SCHEMBL25146634 0.74 NMT1 (0.32) NMT1
SCHEMBL14732763 0.73 EPHX2 (0.62) CTSSCTSKEPHX2PRMT6
SCHEMBL25453297 0.73 CASR (0.51) CTSSCTSKDRD2DRD4DRD3
SCHEMBL649582 0.73 HRH3 (0.50) CTSSCTSKHTR7
SCHEMBL17426493 0.72 PDCD1 (0.45) CTSSCTSKHTR7PTGER1PTGER4
SCHEMBL4316686 0.71 AGXT (0.50) CTSSCTSK
SCHEMBL16526753 0.71 TGFBR1 (0.45) PDE4APDE4DCTSSCTSKHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220411426-A1 SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2022-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411426-A1 SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF IDE, SI, GPR119 PDE4A 2160/4885PDE4B 2017/4885PDE4C 2845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.